Peer-reviewedCC BYFrontiers in oncology16 Oct 2026

Efficacy and toxicities of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for unresectable pancreatic cancer: a systematic review and meta-analysis

Chunle Hu¹
Li Zhan²
Yanhui Li¹
Xiawei Ren³
Zhiyong Yu⁴

4 affiliations

¹The First Clinical Institute, Zunyi Medical University , ,
²School of Clinical Medicine, Southwest Medical University , ,
³The First Clinical Medical College, Xinjiang Medical University , ,
⁴Department of General Surgery, Affiliated Hospital of Zunyi Medical University , ,

Read full text PDF Cite

FOLFIRINOX vs. gemcitabine/nab-paclitaxel for metastatic pancreatic cancer: A real-world study
Jee Hoon Kim, See Young Lee, Galam Leem +9
Translational Oncology26 Oct 2026Peer-reviewedCC BY-NC 4.0Full textOncologyPMC
Cadonilimab plus gemcitabine and cisplatin as first-line treatment for unresectable locally advanced or metastatic biliary tract malignancies: the phase II bicureX clinical trial
Ji Ma, Tao Wang, Yichen Zheng +7
Nature Communications19 Oct 2026Peer-reviewedCC BY-NC-ND 4.0Full textSurgery & anaesthesiaCrossref
Comparative Evaluation of Concurrent Carboplatin-Paclitaxel Versus Cisplatin-Etoposide Chemoradiotherapy in Unresectable Non-small Cell Lung Cancer: A Prospective Randomized Study
Yamini Kumar, Bala Venkat Subramanian, G V Deepthi +2
Cureus16 Oct 2026Peer-reviewedCC BYFull textGeneral medicineEurope PMC
A Phase I Study of Nab-Paclitaxel, Gemcitabine and AZD1775 for Treatment of Metastatic Adenocarcinoma of the Pancreas: ECOG-ACRIN EA2131
Jennifer R. Eads, Ju-Whei Lee, Cheng E. Chee +6
Clinical colorectal cancer2 Sep 2026Peer-reviewedCC BY-NC-NDFull textOncologyPMC
Surufatinib and camrelizumab plus nab-paclitaxel–gemcitabine as first-line treatment for metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study
Yudong Yuan, Dongdong Zhang, Yuying Li +1
Frontiers in Pharmacology5 Nov 2026Peer-reviewedCC BY 4.0Pharmacology & toxicologyFrontiersCrossref

Cite

BibTeX RIS

BibTeX

@article{hu2026efficacy,
  title = {{Efficacy and toxicities of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for unresectable pancreatic cancer: a systematic review and meta-analysis}},
  author = {Chunle Hu and Li Zhan and Yanhui Li and Xiawei Ren and Zhiyong Yu},
  journal = {Frontiers in oncology},
  year = {2026},
  month = oct,
  url = {https://europepmc.org/article/PMC/PMC13655002},
  note = {CC BY},
}

RIS

TY  - JOUR
TI  - Efficacy and toxicities of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for unresectable pancreatic cancer: a systematic review and meta-analysis
AU  - Chunle Hu
AU  - Li Zhan
AU  - Yanhui Li
AU  - Xiawei Ren
AU  - Zhiyong Yu
PY  - 2026
DA  - 2026/10/16
JO  - Frontiers in oncology
UR  - https://europepmc.org/article/PMC/PMC13655002
SN  - 2234-943X
ER  -

Related

Cite